Preclinical studies of VS‐505: a non‐absorbable highly effective phosphate binder

No abstract is available for this paper.

• Publication year

  2016

• Venue

  British Journal of Pharmacology

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/bph.13510PMID 27156057PMCID PMC4919576
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Preclinical studies of VS‐505: a non‐absorbable highly effective phosphate binder

  2016cited by this paper
• Implementing guidelines on reporting research using animals (ARRIVE etc.): new requirements for publication in BJP

  2015cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: Voltage‐gated ion channels

  2015cited by this paper
• The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands

  2015cited by this paper
• Experimental design and analysis and their reporting: new guidance for publication in BJP

  2015cited by this paper
• The Concise Guide to PHARMACOLOGY 2015/16: Transporters

  2015cited by this paper
• Treatment of Hyperphosphatemia With Bixalomer in Japanese Patients on Long‐Term Hemodialysis With Gastrointestinal Symptoms

  2014influential reference
• The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials

  2014cited by this paper
• Association of Increased Indoleamine 2, 3‐Dioxygenase With Impaired Natural Killer Cell Activity in Hemodialysis Patients

  2014cited by this paper
• Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.

  2014cited by this paper
• VS-501: a novel, nonabsorbed, calcium- and aluminum-free, highly effective phosphate binder derived from natural plant polymer

  2014cited by this paper
• FGF-23, vascular calcification, and cardiovascular diseases in chronic hemodialysis patients

  2013cited by this paper
• Role of hyperphosphatemia-mediated vascular calcification in cardiovascular outcomes and its management: a review.

  2013cited by this paper
• Mapping the time-dependent effects of paricalcitol on serum calcium, phosphorus and parathyroid hormone levels in 5/6 nephrectomized uremic rats.

  2013cited by this paper
• PA21, a New Iron-Based Noncalcium Phosphate Binder, Prevents Vascular Calcification in Chronic Renal Failure Rats

  2013cited by this paper
• FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients

  2013cited by this paper
• Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis

  2013influential reference
• Phosphate control in end-stage renal disease: barriers and opportunities.

  2013cited by this paper
• Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complications of Secondary Hyperparathyroidism and Vascular Calcification

  2013cited by this paper
• A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease.

  2013cited by this paper
• Two Novel Vitamin D Receptor Modulators with Similar Structures Exhibit Different Hypercalcemic Effects in 5/6 Nephrectomized Uremic Rats

  2013cited by this paper
• Phosphate additives in food--a health risk.

  2012cited by this paper
• [Pathologies of calcium-phosphate homeostasis].

  2012influential reference
• Effects of phosphate binders in moderate CKD.

  2012influential reference
• VS‐105: a novel vitamin D receptor modulator with cardiovascular protective effects

  2011cited by this paper
• Effect of medial calcification on vascular function in uremia.

  2011influential reference
• Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction.

  2011cited by this paper
• Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

  2011influential reference
• Ten-year experience with sevelamer and calcium salts as phosphate binders.

  2010cited by this paper
• Forging forward with 10 burning questions on FGF23 in kidney disease.

  2010cited by this paper
• Animal Research: Reporting In Vivo Experiments: The ARRIVE Guidelines

  2010cited by this paper
• Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy

  2010cited by this paper
• Vitamin D Receptor Activation Mitigates the Impact of Uremia on Endothelial Function in the 5/6 Nephrectomized Rats

  2010cited by this paper
• Serum phosphate and mortality in patients with chronic kidney disease.

  2010influential reference
• Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease.

  2010cited by this paper
• Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis

  2010cited by this paper
• Regulation of rat intestinal Na-dependent phosphate transporters by dietary phosphate.

  2009cited by this paper
• Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease- Mineral and Bone Disorder (CKD-MBD)

  2009cited by this paper
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

  2009cited by this paper
• KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

  2009cited by this paper
• Intestinal npt2b plays a major role in phosphate absorption and homeostasis.

  2009cited by this paper
• Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.

  2009influential reference
• Treatment of hyperphosphatemia with sevelamer hydrochloride in dialysis patients: effects on vascular calcification, bone and a close look into the survival data.

  2008cited by this paper
• Disintegration of solid foods in human stomach.

  2008influential reference
• Differential effects of Vitamin D analogs on calcium transport.

  2007cited by this paper
• Elevated phosphorus modulates vitamin D receptor-mediated gene expression in human vascular smooth muscle cells.

  2007cited by this paper
• Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community.

  2007influential reference
• Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients.

  2006cited by this paper
• The phosphatonins and the regulation of phosphate homeostasis.

  2006cited by this paper
• Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study.

  2005cited by this paper
• FGF-23 is elevated by chronic hyperphosphatemia.

  2004cited by this paper
• Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.

  2004cited by this paper
• On the evolving nature of understanding dialysis-related disorders.

  2003cited by this paper
• K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

  2003cited by this paper
• Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia.

  2003cited by this paper
• A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients.

  1999cited by this paper
• Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.

  1997influential reference
• Open Access Journal of Urology Dovepress Update and Critical Appraisal of Sevelamer in the Management of Chronic Renal Failure

  year unknowncited by this paper

• Efficacy, tolerability, and safety of the oral phosphate binder VS-505 (AP301).

  2024cites this paper
• Secondary hyperparathyroidism in chronic kidney disease: pathophysiology, current treatments and investigational drugs

  2024cites this paper
• Effects of pharmacological inhibition of the sodium‐dependent phosphate cotransporter 2b (NPT2b) on intestinal phosphate absorption in mouse and rat models

  2022cites this paper
• Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease

  2022cites this paper
• Binding and inhibitory activities: A novel oral therapeutic agent for the treatment of hyperphosphataemia rats.

  2022cites this paper
• Fibroblast Growth Factor-23-Klotho Axis in Cardiorenal Syndrome: Mediators and Potential Therapeutic Targets

  2021cites this paper
• Phosphate binders in chronic kidney disease: an updated narrative review of recent data

  2019cites this paper
• Preclinical studies of VS‐505: a non‐absorbable highly effective phosphate binder

  2016cites this paper